---
schema_version: "secwatch.filing_event.v1"
accession: "0001790340-24-000022"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2024-03-01T23:59:59+00:00"
generated_at: "2026-06-05T05:43:12.965908+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Immuneering reports $85.7M cash, net loss $53.5M in 2023; trial milestones ahead

## Summary
- Cash, cash equivalents and marketable securities $85.7M as of Dec 31, 2023; cash runway into 2H 2025.
- Net loss Q4 2023 $15.1M ($0.52 per share); full year net loss $53.5M ($1.88 per share).
- FDA Fast Track designation for IMM-1-104 in pancreatic cancer received Feb 2024.
- Topline Phase 1 data for IMM-1-104 expected March 2024; first patient in Phase 2a expected March 2024.
- First patient dosing in Phase 1/2a trial of IMM-6-415 expected March 2024.

## SEC filing metadata
- accession: 0001790340-24-000022
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2024-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000179034024000022/0001790340-24-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000179034024000022/imrx-20240301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001790340-24-000022
- JSON: https://secwatch.observer/filing/0001790340-24-000022.json
- Plain text: https://secwatch.observer/filing/0001790340-24-000022.txt

## Key facts
- Earnings Releases
  Immuneering Corp reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1790340/000179034024000022/0001790340-24-000022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.